State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

Treatment Strategies for Hematocrit Control in PV

Insights from 2023 ASH Annual Meeting

A. Zhou

Safety Profile of Ruxolitinib in Patients With MF

Icahn School of Medicine at Mount Sinai

D. Tremblay

Waldenstrom’s Macroglobulinemia: Approaching the Newly Diagnosed and…

Indy Hematology Review

S. Treon

Cardiovascular Considerations With (Contemporary) BTKi in the Treatm…

Daniel Addison

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…

ASH 2022 Conference Coverage

M. McMullin

Prevalence and Prediction of Ruxolitinib Treatment Emergent Thromboc…

Insights from 2023 ASH Annual Meeting

D. Tremblay

Diagnosis and Goals of Therapy in PV

Northwestern Medicine Oncology and Hematology

B. Stein

Using Cytoreductive Therapy to Prevent Cardiovascular Events in Pati…

Monia Marchetti

Treatment-Related Quality of Life in MF

Winship Cancer Institute - Emory University

A. Hunter

ASCO 2022 Bendamustine Rituximab vs. Ibrutinib as Primary Therapy fo…

ASCO 2022 Conference Coverage

J. Abeykoon

ASH 2022 Results From the Phase 1/2 BRUIN Study: Safety & Tolerabili…

ASH 2022 Conference Coverage

N. Shah

SOHO Italy 2023: How I Manage Waldenstrom’s Macroglobulinemia in the…

5th SOHO Italy Annual Conference

S. Treon

Managing Newly Diagnosed MM in 2023

Indy Hematology Review

S. Usmani

ASCO® 2023 Insights: "BELLWAVE-003 - A Phase 2 Dose Escalation, Conf…

Insights from 2023 ASCO® Annual Meeting

G. Perini

ASH 2023 Insights: "Ibrutinib and Venetoclax in Symptomatic, Treatme…

Insights from 2023 ASH Annual Meeting

J. Castillo

Emerging and Current Treatment of Amyloidosis and Waldenstrom’s Macr…

Indy Hematology Review

M. Gertz

EHA 2024 Insights: CD20-Targeted CAR-T Therapy for BTKi-Refractory W…

Insights from 2024 EHA Annual Meeting

M. Shadman

ASCO® 2023 Insights: "Long-Term Safety With ≥12 Months of Pirtobruti…

Insights from 2023 ASCO® Annual Meeting

C. Coombs

ASH 2022: Zanubrutinib in Acalabrutinib-Intolerant Patients With B-C…

ASH 2022 Conference Coverage

M. Shadman